Department of Surgery, University of Pittsburgh Medical Center Pittsburgh, Pittsburgh, PA, USA.
School of Medicine, University of Pittsburgh Medical Center Pittsburgh, Pittsburgh, PA, USA.
Gen Thorac Cardiovasc Surg. 2022 Aug;70(8):705-713. doi: 10.1007/s11748-022-01778-7. Epub 2022 Feb 10.
This study evaluates the impact of early post-operative hyperlactatemia on outcomes after left ventricular assist device (LVAD) implantation.
Adults undergoing contemporary LVAD implantation between 2009 to 2018 were included. Peak post-operative (within 24-h) lactate level was analyzed. The cohort was stratified into patients with and without post-operative hyperlactatemia, which was defined as peak > 3.5 mMol/L. The primary outcome was survival, and secondary outcomes included post-implant adverse events. Sub-analysis was performed to evaluate the impact of time for lactate normalization, define as lactate < 2 mMol/L. Multivariable cox regression was used for risk-adjustment.
A total of 190 patients were included. 49.5% experienced early post-operative hyperlactatemia. Patients with post-operative hyperlactatemia had significantly higher rates of post-implant complications including re-operation, renal failure, and hepatic dysfunction (all, p ≤ 0.05). The post-operative hyperlactatemia group also had significantly higher 90-day and 1-year mortality rates following LVAD implantation (both, p ≤ 0.05). In multivariable analysis, post-operative hyperlactatemia (HR 1.69, 95% CI 1.09-2.60, p = 0.02) was an independent predictor of overall mortality following LVAD implantation. Increased time for normalization of lactate also adversely impacted risk-adjusted overall mortality following implantation as a continuous variable (HR 1.02, 95% CI 1.01-1.03, p < .001).
This study demonstrates early post-operative hyperlactatemia is associated with increased morbidity and mortality following LVAD implantation. Even early post-operative lactate trends within the first 24 post-operative hours appear to have a useful role in predicting longitudinal survival following implantation. Careful monitoring of post-operative lactate with measures to normalize levels should be considered in the early care of LVAD patients.
本研究评估了左心室辅助装置(LVAD)植入术后早期高乳酸血症对预后的影响。
纳入 2009 年至 2018 年间接受当代 LVAD 植入术的成年人。分析术后(24 小时内)的峰值乳酸水平。该队列分为术后高乳酸血症患者和无术后高乳酸血症患者,术后高乳酸血症定义为峰值乳酸水平>3.5mmol/L。主要结局是生存,次要结局包括植入后不良事件。进行亚组分析以评估乳酸正常化时间的影响,定义为乳酸水平<2mmol/L。使用多变量 Cox 回归进行风险调整。
共纳入 190 例患者,其中 49.5%的患者出现早期术后高乳酸血症。术后高乳酸血症患者术后并发症发生率更高,包括再次手术、肾衰竭和肝功能障碍(均,p≤0.05)。术后高乳酸血症组 LVAD 植入术后 90 天和 1 年死亡率也显著升高(均,p≤0.05)。多变量分析显示,术后高乳酸血症(HR 1.69,95%CI 1.09-2.60,p=0.02)是 LVAD 植入术后总死亡率的独立预测因素。乳酸正常化时间的增加也作为连续变量对植入术后风险调整的总死亡率产生不利影响(HR 1.02,95%CI 1.01-1.03,p<0.001)。
本研究表明,LVAD 植入术后早期高乳酸血症与发病率和死亡率增加相关。即使在术后 24 小时内早期的乳酸趋势似乎在预测植入后纵向生存方面也具有有用的作用。应在 LVAD 患者的早期治疗中仔细监测术后乳酸并采取措施使其水平正常化。